The reference product exclusivity period under the BPCIA means no biosimilar can rely on the FDAs pembrolizumab safety data until 12 years after first approval which for pembrolizumab (approved September 2014) is September 2026
The co-primary endpoints of the study at 72 weeks were the percentage change in weight from baseline and a body weight reduction of 5% or more (82)
GLP-1-based therapies, such as GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors, improve glucose control through various mechanisms including increased insulin secretion, slower gastric emptying, and reduced postprandial glucagon and food intake
In selected cases of severe, treatment-resistant lymphoedema, surgical options such as liposuction (covered by NICE interventional procedures guidance), lymphaticovenous anastomosis, or vascularised lymph node transfer may be considered at specialist centres, though these remain relatively uncommon
Ipamorelin is a substance known as a secretagogue, which means that it increases the specificity of CJC-1295
It is important to note that weight loss results can vary depending on the type of drug you take and your prescribed dose